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Background: Because of unique roles in wound healing, trophic tissue support, immunomodulation, 
differentiation ability, and immune privileged status, human mesenchymal stem cells (hMSCs), which can be 
easily derived from many adult tissues (e.g. bone marrow (BMSCs) and adipose tissue (AMSCs)), are under 
intense study for the applications of cell and gene therapeutics, as well as tissue engineering and regenerative 
medicine1. Genetic modification of hMSCs could allow for targeted delivery of transgenic therapeutic factors or 
genetically-guided differentiation. Non-viral gene delivery (i.e. cationic polymer- and lipid-mediated) is safer and 
more flexible than immunogenic and mutagenic viral vectors2, but it is less effective, especially in hMSCs (i.e. 
maximum 10-30% transfection)3. As part of an approach to understand molecular mechanisms of non-viral gene 
delivery4 and ‘prime’ cells to be more receptive to transfection5, our lab recently demonstrated that transgene 
expression from lipofected hMSCs can be increased about 10-fold by priming cells, 30 mins before plasmid 
DNA (pDNA) transfection, with 100 nM dexamethasone (DEX), a glucocorticoid (Gc) drug, relative to EtOH 
vehicle control (VC)6. This work investigates the mechanisms by which Gc priming enhances non-viral gene 
delivery, which are currently unknown. Studies provide insights into the biological processes of Gc priming and 
transfection to inform future gene delivery technologies, and characterize a simple protocol to significantly 
enhance non-viral gene delivery of therapeutic transgenes for future clinical applications. 
Results & Discussion: DEX significantly increased transgene expression over VC in all BMSCs and AMSCs, 
derived from multiple human donors (i.e. 5- to 14-fold) (Fig. 1A). Enhanced non-viral gene delivery by Gc 
treatment was mediated by binding of the cytosolic glucocorticoid receptor (GR) (Fig. 1B), as treatment with 
other steroids resulted in no enhancement. Inhibiting nuclear import pathways dramatically decreased transgene 
expression in the absence of DEX, but did not decrease the fold-change enhancement by DEX priming. 
Cytoplasmic transport inhibition modestly decreased fold-change enhancement by DEX priming, possibly by 
inhibiting GR or pDNA trafficking. Enhancement by DEX treatment occurs regardless of any pDNA sequence 
element changes. DEX priming did not increase cellular or nuclear internalization of pDNA, or increase 
transgene RNA expression. DEX treatment modulated endogenous gene expression to increase hMSC total 
protein synthesis after transfection, contributing to increased transgenic protein production. Studying 
mechanisms of priming cells for transfection provides greater understanding of molecular parameters important 
to gene delivery and characterizes practical protocols to improve delivery of clinically-relevant transgenes.  
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Figure 1-- A) BMSC and AMSC luciferase transgene expression treated with EtOH vehicle control (VC) or 150 
nM DEX B) Summary of investigations into molecular mechanisms of hMSC transfection and DEX priming (e.g. 
pDNA internalization and intracellular transport, endogenous signaling and gene expression, pDNA sequence 
interactions, transgene transcription and translation). 
